Kornimate/medical-research-clean huggingface dataset:
the in vivo effect of medical and surgical glaucoma treatments on the schlemm's canal micro-structure

Conditions: Glaucoma; Cataract

Summary: the purpose of our current series of studies is to evaluate different glaucoma treatments in vivo effect on the conventional outflow pathway, and specifically on the schlemm's canal (sc) anatomy using enhanced depth imaging (edi)-optical coherence tomography (oct) . the images will be taken as part of the patients routine medical follow up (before starting the treatment, and 1,4 and 12 weeks afterwards) diameter, cross-sectional area and volume will be measured using commercially available 3-dimensional reconstruction. the series of studies will be divided into 3 branches, each branch contains different treatments.for each treatment different patients will be recruited. the branches are as following- 1. the surgical branch- 1. before and after trabeculotomy 2. before and after cataract surgery 3. before and after vitrectomy surgery 4. before and after xen™ gel stent implant 2. the pharmacological branch- 1. before and during the treatment with prostaglandins analogs 2. before and during the treatment with alpha blockers 3. before and during the treatment with beta blockers 4. before and during the treatment with carbonic anhydrase inhibitor 3. the laser branch- 1. before and after trabeculoplasty 2. before and after laser iridotomy 3. before and after yag capsulotomy laser


Eligibility criteria:
inclusion criteria: 1. male or female of any race, at least 18 years of age. 2. has provided verbal and written informed consent. 3. able and willing to follow instructions, including participation in all study assessments and visits. 4. has been referred to one of the treatments mentioned exclusion criteria: 1. has history of ocular conditions that may affect the sc structure (e.g., ocular neovascularization, anterior segment congenital anomalies) 2. subject uncooperativeness that restricts adequate examination of iop, ocular fundus or 3. any ocular or systemic conditions that may reduce oct image quality (e.g., severe dry eye syndrome, visually significant cataract, limbal opacities, nystagmus, parkinsonism, etc), 4. pregnant women or male or female younger than 18 years of age
a study of durvalumab (medi4736) and monalizumab in solid tumors

Conditions: Advanced Solid Tumors

Summary: this is a multicenter, open-label, dose-escalation, dose-exploration and dose-expansion study to evaluate the safety, tolerability, antitumor activity, pharmacokinetic (pk), pharmacodynamics, and immunogenicity of durvalumab (medi4736) in combination with monalizumab (iph2201) in adult participants with selected advanced solid tumors and the combination of durvalumab and monalizumab (iph2201) standard of care systemic therapy with or without biological agent and monalizumab (iph2201) with biological agent administered to participants with recurrent or metastatic colorectal cancer (crc).

the study consists of 3 parts: dose escalation (part 1), dose expansion (part 2), and dose exploration (part 3). part 1 will evaluate dose escalation of durvalumab in combination with monalizumab in adult participants with select advanced solid tumor malignancies. part 2 will evaluate further the identified dose of durvalumab in combination with monalizumab from part 1 in adult participants with select advanced solid tumor malignancies. part 3 will evaluate dose exploration of durvalumab in combination with monalizumab and standard of care systemic therapy with or without biological agent, and monalizumab in combination with biological agent in adult participants with crc.

Eligibility criteria:
inclusion criteria: 1. participants must have histologic documentation of advanced recurrent or metastatic cancer. 2. participants must be at the recurrent/metastatic setting, with selected advanced solid tumors. 3. participants must have at least one lesion that is measurable by recist v1.1 4. part 3, dose exploration, crc participants can be treatment naïve but should not have received more than two line of systemic therapy in the recurrent/metastatic setting. exclusion criteria 1. prior treatment with immunotherapy agents. prior treatment with antitumor vaccines may be permitted upon discussion with the medical monitor. 2. prior participation in clinical studies that include durvalumab alone or in combination, where the study has registrational intent and the analyses for the primary endpoint have not yet been completed 3. receipt of any conventional or investigational anticancer therapy within 4 weeks prior to the first dose of study treatment 4. any concurrent chemotherapy, immunotherapy, biologic or hormonal therapy for cancer treatment. concurrent use of hormones for non-cancer-related conditions is acceptable.

Keywords: colorectal, colon, crc, solid tumors, check point inhibitors, immunotherapy, metastatic
monogenic kidney stone - genetic testing

Conditions: Rare Kidney Stone Diseases

Summary: this study will attempt to identify the specific gene (coded in the dna) and changes (mutations) within that gene that are the cause of monogenic kidney stone disease. this study will help researchers determine the characteristics of the stone disease associated with specific genes and mutations. this information may help develop more effective treatments for monogenic kidney stone diseases.

have a blood test (about 2 teaspoons; ½ to 1 teaspoons for children) or buccal cell collection for dna or rna isolation • complete a kidney stone history questionnaire in addition to the above testing, family members may be asked to participate in the following: • complete a 24 hr. urine collection your samples will undergo genetic testing. we will share the results with your local doctor. all family members, of a patient whose genetic testing showed no known mutations, will not be tested. these samples will be stored for future research.

Eligibility criteria:
inclusion criteria: participants meet at least one of the following criteria: 1. patients \<18yrs with a history of kidney stones, and/or nephrocalcinosis, or 2. patients \>18yrs with a history of kidney stones, and/or nephrocalcinosis and at least one of the following: 1. family history of stones or nephrocalcinosis or unexplained kidney failure 2. growth retardation 3. metabolic bone disease 4. unusual stone composition or pathologic or urinary crystals 5. proteinuria 6. reduced glomerular filtration rate (gfr) 7. hypomagnesemia or hypophosphatemia or hypercalcemia 8. increased oxalate 9. renal cysts, or 3. patients with a high clinical suspicion for a monogenic kidney stone disease or a disorder of calcium metabolism or 4. patients previously enrolled in the rare kidney stone consortium 6406 protocol (identified as legacy samples), "genetic characterization and genotype/phenotype correlations in primary hyperoxaluria." these patients have already consented for their samples to be used in genetic research and that consent will serve to enroll them in this study, or 5. patients previously enrolled in the rare kidney stone consortium 6403 protocol (identified as legacy samples), "screening for dent disease mutations in patients with proteinuria or hypercalciuria and calcium urolithiasis." these patients have already consented for their samples to be used in genetic research and that consent will serve to enroll them in this study, or 6. family member of a patient that meets at least one of the above criteria exclusion criteria: 1. stone formers who do not meet the inclusion criteria for clinical suspicion of one of the monogenic kidney stone diseases 2. unwilling or unable to provide consent/assent

Keywords: primary hyperoxaluria (ph) hyperoxaluria ph ph 1 ph 2 ph 3 dent disease dent 1 dent 2 cystinuria aprt deficiency 24-hydroxylase deficiency cyp24a1
self-efficacy enhancing interviewing techniques study

Conditions: Diabetes; Depression; Anxiety; Asthma; Post-Traumatic Stress Disorder

Summary: patient self-efficacy, or confidence in one's ability to take the necessary steps to achieve a goal, has been shown to influence a number of important health behaviors and outcomes. however, current ways of increasing patient self-efficacy are time and labor intensive and occur away from doctor visits, where most health care is delivered. we developed, and are testing in a study the effectiveness of a new way of teaching doctors how to talk to patients during office visits in a way that will boost their patients' self-efficacy for changing important health behaviors.


Eligibility criteria:
inclusion criteria: * family medicine or internal medicine residents in training at the university of california davis medical center exclusion criteria: * none

Keywords: self-efficacy chronic illness health behavior education, medical, residency
transcriptome, proteome and microbiome profile in periodontal and peri-implant diseases

Conditions: Peri-implantitis; Periodontitis

Summary: 1. to investigate the transcriptomic profile of periodontitis and peri-implantitis. patients with defined periodontitis, at two non-adjacent teeth and peri-implantitis at ≥ one implant in function of ≥ one year, will be included to investigate the gene expression profile in tissue affected by periodontitis and peri-implantitis. subjects will undergo a full-mouth examination performed by a calibrated examiner, including assessment of caries, bone abnormalities and infections according to intraoral x-ray, plaque index and pocket probing depth, suppuration, bleeding on probing, alveolar bone loss, and the number of teeth. during surgical intervention, tissue biopsies (two specimens per site) will be collected by a periodontist from site with ongoing periodontitis and site from ongoing peri-implantitis. 2. to study the microbiome and biomarker profile associated with periodontitis and peri- implantitis. patients with defined periodontitis, at two non-adjacent teeth and peri-implantitis at ≥ one implant in function of ≥ one year, will be included in this study to determine the bacteria composition, cytokine profile and inflammatory biomarkers profile. subjects will undergo a full-mouth examination performed by a calibrated examiner, including assessment of caries, bone abnormalities and infections according to intraoral x-ray, plaque index and pocket probing depth, suppuration, bleeding on probing, alveolar bone loss, and number of teeth. peri-implant crevicular fluid (picf), gingival crevicular fluid (gcf), saliva and submucosal/subgingival plaque will be collected.the presence and composition of periodontal and peri-implant plaque samples are investigated.


Eligibility criteria:
inclusion criteria: ≥18 years of age defined periodontitis at two non-adjacent teeth defined peri-implantitis at ≥1 implant signed informed consent exclusion criteria: surgical intervention of periodontitis and/or peri-implantitis during last 6 months. local or systemic use of antibiotics during last 6 months.

Keywords: peri-implantitis periodontitis
evaluation and comparison of the efficacy of triphala mouthwash and 0.2% chlorhexidine

Conditions: Periodontal Disease

Summary: the purpose of this study is to evaluate the usefulness of triphala mouthwash in comparison with the gold standard chlorhexidine in hospitalized and periodontally diseased patients.


Eligibility criteria:
inclusion criteria: * age group of 20-65 years having periodontal diseases according to american academy of periodontology (aap) classification 1999 exclusion criteria: * patients seeking any periodontal treatment during the course of study

Keywords: chlorhexidine gingivitis periodontitis
community support program for lung cancer screening

Conditions: Lung Cancer; Behavior

Summary: the research study aims to create a program for lung cancer screening attendance

the overall objective of this project is to demonstrate the impact of a community support program (csp) on improving adherence to lcs follow-up guidelines in an urban environment. the project aims to collaborate with community partners to develop an infrastructure and iterative process to provide social support to community members that facilitates obtaining their follow-up ldct for lcs. it utilizes novel population level data that includes geospatial analysis of neighborhood-level data of patients residing in philadelphia who have received a ldct for lcs. this allows for targeted community level interventions and the ability to evaluate impact on a population level. a community support program representative will reach out to eligible patients via telephone. the csp representative and patient navigator will communicate with consented patient directly, assist with travel and the appointment. the pn will log the date of the appointment, zip code of the patient and the adherence (or lack of) of the appointment completion. we will utilize lyft transportation vouchers to provide rides to participants from their home location in west philadelphia to and from the penn medicine downtown hospital locations on the day of their ldct.

Eligibility criteria:
inclusion criteria: * upcoming or missed follow-up ldct (low dose ct) * west philadelphia resident * between 18-89 years' old exclusion criteria: * no upcoming ldct * lives outside west philadelphia * outside age range

Keywords: screening adherence
efficacy of myo-inositol in preventing gestational diabetes in high-risk pregnant women

Conditions: Gestational Diabetes

Summary: the aim of this study is to evaluate the efficacy of myo-inositol in preventing gestational diabetes in high risk pregnant women.


Eligibility criteria:
inclusion criteria: 60 women in their first trimester of pregnancy affected by one or more of the following risk factors: * glycemia levels \> 92 mg/dl * bmi \> 30 * at least a parent or a brother (or sister)affected by diabetes * pre-existing pregnancy with gestational diabetes exclusion criteria: * pregnant women affected by pregestational diabetes * twin pregnancy * patients affected by pre-existing diseases in pregnancy (diabetes excluded) * patients affected by chronic disorders

Keywords: diabetes pregnancy myo-inositol
trier social stress test in virtual reality

Conditions: Stress, Psychological; Stress, Physiological

Summary: background the trier social stress test (tsst) is a valid and gold standard way for inducing psychosocial stress and is widely used in research and diagnostics. one of the downsides of the tsst is the difficulty to maintain the same experimental conditions repeatedly. a tsst in virtual reality (tsst-vr) is constant and requires far less time and personnel. our tsst-vr version consist of three stress levels (no stress, moderate stress, high stress), a novelty in this field. aim the aim is to investigate whether there is a statistically significantly greater increase directly after the tsst-vr in psychological and physiological stress parameters in the moderate and high stress levels compared to the no stress condition (control). method a randomized controlled trial is conducted in healthy adults, with the three stress levels as conditions. cortisol and questionnaires on anxiety and physical arousal are measured at baseline, during and after the tsst. heart rate is measured continuously and adverse events are monitored.


Eligibility criteria:
inclusion criteria: * healthy participants, not having a psychiatric diagnosis in the last three years or currently having an endocrine disorders * aged between 18 and 65 years * good understanding of the dutch language * normal or corrected-to-normal vision and hearing exclusion criteria: * history of photosensitive epilepsy * hearing loss * pregnant woman * women who breastfeed * taking heart rate altering medication such as beta-blockers. pregnant woman and woman who breastfeed are excluded because they have a different hormone levels which can intervene with the stress reaction.
ace inhibitors to decrease lymphoid fibrosis in antiretroviral-treated, hiv-infected patients: a pilot study

Conditions: HIV

Summary: the investigators propose a proof-of-concept, pathogenesis-oriented, randomized, placebo-controlled pilot study to assess whether the addition of an angiotensin converting enzyme (ace) inhibitor to standard highly active antiretroviral therapy (haart) reverses lymphoid fibrosis, and whether this leads to more effective hiv-specific host immune responses and an accelerated clearance of the latent reservoir.


Eligibility criteria:
inclusion criteria include: * stable haart with maintenance of plasma hiv rna levels below level of detection (\< 40-75 copies/ml) for ≥ 12 months * \> 90% adherence to haart within preceding 30 days exclusion criteria include: * screening systolic blood pressure \< 110mm hg or diastolic blood pressure \< 60mm hg * current use of any ace inhibitor, angiotensin receptor blocker, or aldosterone antagonist * known diabetes mellitus or cardiovascular/kidney/collagen vascular disease * pregnant/breastfeeding women.

Keywords: hiv lymphoid fibrosis
psycho-educational program in increasing knowledge and satisfaction and decreasing distress in younger patients with cancer receiving treatment

Conditions: Malignant Neoplasm; Psychosocial Effects of Cancer and Its Treatment

Summary: this pilot clinical trial studies psycho-educational program in increasing knowledge and satisfaction and decreasing distress in younger patients with cancer receiving treatment. psycho-educational program may increase knowledge and satisfaction and decrease distress in younger patients with cancer receiving treatment

primary objectives: i. providing a psycho-educational group to young adults while examining the feasibility of such a group with patients on treatment. ii. examining effectiveness of the program through evaluating pre-post changes in participant distress, evaluating increases in participant' knowledge regarding disease issues and coping, and evaluating participant satisfaction. outline: patients undergo psycho-educational program comprising medical/symptom management and communication with a medical team, coping skills, self image, and relationships and communication for 1.5 hours once weekly for 6 weeks. after completion of study treatment, patients are followed up for 30 days.

Eligibility criteria:
inclusion criteria: * currently in active treatment (diagnosed and receiving treatment within 2 weeks of initial study enrollment; active treatment includes currently receiving any of the following: chemotherapy, radiation therapy, maintenance drugs, surgery, clinical trial enrollment, or current relapse/secondary malignancy) * inpatient or outpatient * cancer diagnosis * physician approval * informed consent exclusion criteria: * significant psychiatric or developmental issues, as determined by screening interview conducted by psychologist or clinical social worker * currently off treatment (longer than 2 weeks at the time of enrollment) * in isolation or with isolation precautions * non-english speaking
myofascial stretch with and without functional massage in children with cerebral palsy

Conditions: Cerebral Palsy, Functional Massage, Myofacial Stretch

Summary: cerebral palsy is one of the most common childhood disabilities, and it occurs with an incidence of 2-2.5 per 1000 living births. children with cp have various impairments including neuromuscular and musculoskeletal problems such as spasticity, dyscoordination, loss of selective motor control, and weakness. cp can be classified according to the severity of motor deficits as mild, moderate, or severe. several other classification systems exist based on the pathophysiology, etiology, and distribution of motor deficits. the aim of the study to evaluate the effects of functional massage and myofascial stretch on spasticity and motor function of cp children. study will be conducted in 22 patients in experimental and control group. pre and post values will be evaluated. the tools used will be modified ashworth scale (mas) and gross motor function measure (gmfm). the significance of this study is that it will define for us that to how much extent we can improve the spastic and painful condition of lower limb of cp child. data will be analyzed using spss 22.0 mean and standard deviation will be calculated. appropriate the statistical test will be used after checking normality of data.


Eligibility criteria:
inclusion criteria: * age of 6 and 12 year * both genders * children between level ⅰ- ⅳ based on gross motor classification system(gmfcs) exclusion criteria: * the existence of dyskinesia or dystonia * history of muscle lengthening surgery * presence of uncontrolled seizures
safety, pharmacokinetics and efficacy study of cvt-301 inpatients with parkinson's disease and "off" episodes

Conditions: Idiopathic Parkinson's Disease

Summary: the purpose of this study is to determine the safety, efficacy and pharmacokinetics following administration of cvt-301 in treatment of "off" episodes in parkinson's disease patients.

treatment options for patients with motor response fluctuations are limited. most commonly, "off" episodes are managed by adjusting the dose interval of their standard oral medications or by self-administration of unscheduled doses of oral parkinson's medication. due to the variability in levodopa absorption following oral dosing, resumption of motor function is unreliable and may be delayed for an hour or more. cvt-301 delivers levodopa using a simple inhaler, resulting in rapid increases in levodopa blood levels and is expected to result in rapid restoration in motor function for patients experiencing "off" episodes.

Eligibility criteria:
inclusion criteria: * idiopathic parkinson's disease (pd) diagnosed between the ages of 30 and 80 years; * hoehn and yahr stage 1-3 in an "on" state; * require levodopa-containing medication regimen at least 4 times during the waking day; * experience motor fluctuations with a minimum of 2 hours of average daily "off" time per waking day (excluding early morning "off" time) and demonstrate levodopa responsiveness; * are on stable pd medication regimen. exclusion criteria: * pregnant or lactating females; * previous surgery for pd or plan to have stereotactic surgery during the study period; * history of psychotic symptoms requiring treatment, or suicide ideation or attempt within last year; * adequate lung function as measured by spirometry; * any significant condition, severe concurrent disease, abnormality or finding that would make patients unsuitable or may compromise patient safety.

Keywords: parkinson's disease motor fluctuations levodopa inhaled drugs motor fluctuation ("off episodes")
a cohort establishment study of total management of ovarian cancer

Conditions: Tumor of Female Reproductive System; Ovarian Cancer

Summary: a cohort establishment study of total management of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).

1. to investigate the effects of surgery, chemotherapy, maintenance therapy and related factors on the prognosis and quality of life of patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer); 2. to study the postoperative recovery of patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer), perioperative complications, adverse reactions after chemotherapy, adverse reactions during targeted drug maintenance therapy, and explore possible effective preventive measures; 3. the prognostic factors of ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) were analyzed; 4. to study the efficacy and safety of parpi in clinical application in patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer).

Eligibility criteria:
inclusion criteria: 1. patients diagnosed with ovarian cancer (including fallopian tube cancer, primary peritoneal cancer) and intended to be treated in our hospital; 2. can cooperate with later follow-up. exclusion criteria: 1. patients with other malignant tumors or previous history of other malignant tumors; 2. have cognitive impairment.

Keywords: ovarian cancer cohort study whole-process management